Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MAPKAPK2 (mitogen-activated protein kinase-activated protein kinase 2)

Written2010-04Roberta Felix, Veruska Alves, Andre Vettore, Gisele Colleoni
Laboratory of Cancer Molecular Biology, Federal University of Sao Paulo UNIFESP/EPM, Sao Paulo, Brazil

(Note : for Links provided by Atlas : click)

Identity

Other aliasMAPKAPK-2
MK2
HGNC (Hugo) MAPKAPK2
LocusID (NCBI) 9261
Atlas_Id 41295
Location 1q32.1  [Link to chromosome band 1q32]
Location_base_pair Starts at 206685020 and ends at 206734285 bp from pter ( according to hg19-Feb_2009)  [Mapping MAPKAPK2.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
MAPKAPK2 (1q32.1) / RASSF5 (1q32.1)MAPKAPK2 (1q32.1) / SRGAP2 (1q32.1)
Note MAPKAPK2 is involved in many cellular processes including: stress and inflammatory response, nuclear export, gene expression regulation and cell proliferation, acting with p38 MAP gene.

DNA/RNA

Note MAPKAPK2 encodes a member of the Ser/Thr protein kinase regulated through direct phosphorylation by p38 MAP kinase. Inhibition of the p38 MAPK pathway could be a possible target to inflammatory diseases therapy. Unfortunately, blocking p38 MAPK activation "in vivo" implies in high toxicity and it does not have oral bioavailability. MAPKAPK2/MK2 inhibitors acting downstream of p38 could be reasonable solutions to overcome this problem (Duraisamy et al., 2008).
Description Size 49,338 bases, starts at 204924912 and ends at 204974256 bp from pter with plus strand orientation.
Transcription We found some discordant information regarding MAPKAPK2 splice variants. Kervinen et al. 2006, described that the human MAPKAPK2 gene encodes two alternatively spliced transcripts and also that this gene contains 14 different introns (13 gt-ag, 1 gc-ag). Transcription produces 9 different mRNAs, 8 alternatively spliced variants and 1 unspliced form. There are 5 probable alternative promoters and 3 validated alternative polyadenylation sites. The mRNAs appear to differ by truncation of the 5' end, presence or absence of 7 cassette exons, overlapping exons with different boundaries, alternative splicing or retention of 3 introns.
Pseudogene ATF4C - Cyclic AMP-dependent transcription factor ATF-4, localized at chromosome 17, location: 17q25.1.

Protein

Description MAPKAPK2 has two alternatively spliced transcripts, encoding 400 and 370 amino acids, with sequence heterogeneity from Lys-353 to the C-terminus. Crystal structure shows: 1) an autoinhibitory domain, consisting of 328-370 residues; 2) a helix-turn-helix structure that occupies the substrate-binding cleft of the kinase domain and inhibits kinase function (ter Haar et al., 2007).
Localisation The 400-residue MAPKAPK2 (isoform 1) consists of an N-terminal Pro-rich region, a kinase domain, an autoinhibitory domains, and C-terminal nuclear export (NES) and nuclear localization (NLS) signals. The 1-370 isoform (isoform 2) lacks NES and NLS, consistent with its presence only in the cytoplasm. MAPKAPK2 also phosphorylates proteins found in both the nucleus (cAMP-response element-binding protein, or CREB) and cytoplasm (HSP25/27 and LSP-1) (Kervinen et al., 2006).
Function MAPKAPK2 is required for both cytokines production and cell migration (Kotlyarov et al., 2002).
MAPKAPK2 is activated upon stress by p38 MAPK, which binds C terminus of MAPKAPK2, leading to subsequently phosphorylation of its regulatory sites. After activation, MAPKAPK2 is transferred from nucleus to cytoplasm, and cotransport p38 to the new localization. In murine knockout model, MAPKAPK2 blockage leads to a dramatic reduction of tumor necrosis factor (TNF) production in response to lipopolysaccharide (Kotlyarov et al., 2002). One of the major substrates of MAPKAPK2 is the heat shock protein HSP27, which stimulates actin polymerization in order to facilitate recovery from destruction of cytoskeleton during cellular stresses.
Homology Isoform 1 and 2 see figure below.
 

Mutations

Note There is one described mutation: position 804 of mRNA, allele change GCC to GGC. At protein level, residue change A [Ala] to G [Gly].

Implicated in

Note
  
Entity Multiple myeloma (MM)
Note Hideshima et al. 2004 have shown that overexpression of HSP27 confers resistance to bortezomib, a proteasome inhibitor currently used as front line MM therapy, combined with corticosteroids and immunomodulatory drugs, such as thalidomide and lenalidomide. Therefore, overexpression of MAPKAPK2 could be related to MM resistance to chemotherapy. They hypothesized that inhibition of MAPKAPK2 activity could augment bortezomib cytotoxicity by down regulating HSP27. Felix et al. 2009, at their gene expression studies, supported further exploitation of this pathway as therapeutic target in MM, although immunohistochemistry did not show high frequency of protein expression in MM (21%) (Felix et al., 2009).
 
Panel showing bone marrow samples of MM cases: A - plasma cells nuclear and cytoplasmatic positivity for MAPKAPK2; B - sample negative for MAPKAPK2 (400X).
  
  
Entity Bladder cancer
Note Kumar et al. 2010, showed that overexpression of the matrix metalloproteinases MMP-2 and MMP-9 have prognostic value in transitional cell carcinoma of bladder. p38 MAPK modulated MMP-2/9 mRNA expression and MMP-2/9 activity as mediators of tumor cells invasive capacity. Therefore, p38 MAPK inhibition blocks MMP-2/9 activities mediated by MAPKAPK2 (Kumar et al., 2010).
  
  
Entity Skin tumor
Note Using the two-stage chemical carcinogenesis model, Johansen et al. 2009 studied the effect of MAPKAPK2-deficiency and TNF-alpha-deficiency on skin tumor development in mice. Their findings demonstrate a dual role of MAPKAPK2 in the early stages of tumor promotion through regulation of both the inflammatory response and apoptosis of DNA-damaged cells. These results also identify MAPKAPK2 as a possible target for skin carcinoma therapy (Johansen et al., 2009).
  
  
Entity Prostate cancer
Note TGFbeta is an important regulator of cell adhesion and motility in a variety of cell types. p38 MAP kinase is necessary for TGFbeta -mediated up-regulation of matrix metalloproteinase type 2 (MMP-2), as well as TGFbeta -dependent increases in prostate cell invasion. Xu et al. 2006 demonstrated, after transient transfection, that both MAPKAPK2 and HSP27 are necessary for TGFbeta -mediated increases in MMP-2 activity in any cell type, as well as prostate cancer cells (Xu et al., 2006).
  
  
Entity Alzheimer's disease (AD)
Note Culbert et al. 2006 suggested that MAPKAPK2 plays a role in neuroinflammatory and neurodegenerative diseases, such as AD. The MAPKAPK2 activation and expression were increased in lipopolysaccharide (LPS) + interferon gamma-stimulated microglial cells, demonstrating MAPKAPK2 ability in eliciting a pro-inflammatory response. Again, MAPKAPK2 pathway can be considered a target for control of this degenerative brain disease.
  
  
Entity Psoriatic skin
Note Alterations in this specific signal transduction pathway may be involved in increased expression of proinflammatory cytokines in inflammatory diseases (Johansen et al., 2006). The increased activation of MAPKAPK2 is responsible for the elevated TNFalpha protein expression in psoriatic skin, making this pathway a potential target in the treatment of psoriasis (Johansen et al., 2006).
  

Bibliography

MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease.
Culbert AA, Skaper SD, Howlett DR, Evans NA, Facci L, Soden PE, Seymour ZM, Guillot F, Gaestel M, Richardson JC.
J Biol Chem. 2006 Aug 18;281(33):23658-67. Epub 2006 Jun 14.
PMID 16774924
 
MK2: a novel molecular target for anti-inflammatory therapy.
Duraisamy S, Bajpai M, Bughani U, Dastidar SG, Ray A, Chopra P.
Expert Opin Ther Targets. 2008 Aug;12(8):921-36.
PMID 18620516
 
SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.
Felix RS, Colleoni GW, Caballero OL, Yamamoto M, Almeida MS, Andrade VC, Chauffaille Mde L, Silva WA Jr, Begnami MD, Soares FA, Simpson AJ, Zago MA, Vettore AL.
Cancer Lett. 2009 Jun 8;278(1):41-8. Epub 2009 Jan 25.
PMID 19171422
 
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC.
Oncogene. 2004 Nov 18;23(54):8766-76.
PMID 15480425
 
MK2 regulates the early stages of skin tumor promotion.
Johansen C, Vestergaard C, Kragballe K, Kollias G, Gaestel M, Iversen L.
Carcinogenesis. 2009 Dec;30(12):2100-8.
PMID 19808857
 
Effect of construct design on MAPKAP kinase-2 activity, thermodynamic stability and ligand-binding affinity.
Kervinen J, Ma H, Bayoumy S, Schubert C, Milligan C, Lewandowski F, Moriarty K, Desjarlais RL, Ramachandren K, Wang H, Harris CA, Grasberger B, Todd M, Springer BA, Deckman I.
Arch Biochem Biophys. 2006 May 15;449(1-2):47-56. Epub 2006 Mar 31.
PMID 16620770
 
Distinct cellular functions of MK2.
Kotlyarov A, Yannoni Y, Fritz S, Laass K, Telliez JB, Pitman D, Lin LL, Gaestel M.
Mol Cell Biol. 2002 Jul;22(13):4827-35.
PMID 12052889
 
p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity.
Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, Wilson S, Koul HK.
Cancer Res. 2010 Jan 15;70(2):832-41. Epub 2010 Jan 12.
PMID 20068172
 
MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer.
Xu L, Chen S, Bergan RC.
Oncogene. 2006 May 18;25(21):2987-98.
PMID 16407830
 
Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimer.
ter Haar E, Prabhakar P, Liu X, Lepre C.
J Biol Chem. 2007 Mar 30;282(13):9733-9. Epub 2007 Jan 25.
PMID 17255097
 

Citation

This paper should be referenced as such :
Felix, R ; Alves, V ; Vettore, A ; Colleoni, G
MAPKAPK2 (mitogen-activated protein kinase-activated protein kinase 2)
Atlas Genet Cytogenet Oncol Haematol. 2011;15(1):11-14.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/MAPKAPK2ID41295ch1q32.html


Other Leukemias implicated (Data extracted from papers in the Atlas) [ 1 ]
  t(1;9)(q24;q34) RCSD1/ABL1


External links

Nomenclature
HGNC (Hugo)MAPKAPK2   6887
Cards
AtlasMAPKAPK2ID41295ch1q32
Entrez_Gene (NCBI)MAPKAPK2  9261  mitogen-activated protein kinase-activated protein kinase 2
AliasesMAPKAP-K2; MK-2; MK2
GeneCards (Weizmann)MAPKAPK2
Ensembl hg19 (Hinxton)ENSG00000162889 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000162889 [Gene_View]  chr1:206685020-206734285 [Contig_View]  MAPKAPK2 [Vega]
ICGC DataPortalENSG00000162889
TCGA cBioPortalMAPKAPK2
AceView (NCBI)MAPKAPK2
Genatlas (Paris)MAPKAPK2
WikiGenes9261
SOURCE (Princeton)MAPKAPK2
Genetics Home Reference (NIH)MAPKAPK2
Genomic and cartography
GoldenPath hg38 (UCSC)MAPKAPK2  -     chr1:206685020-206734285 +  1q32.1   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)MAPKAPK2  -     1q32.1   [Description]    (hg19-Feb_2009)
EnsemblMAPKAPK2 - 1q32.1 [CytoView hg19]  MAPKAPK2 - 1q32.1 [CytoView hg38]
Mapping of homologs : NCBIMAPKAPK2 [Mapview hg19]  MAPKAPK2 [Mapview hg38]
OMIM602006   
Gene and transcription
Genbank (Entrez)AK307499 BC036060 BC052584 BU621009 X75346
RefSeq transcript (Entrez)NM_004759 NM_032960
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)MAPKAPK2
Cluster EST : UnigeneHs.713747 [ NCBI ]
CGAP (NCI)Hs.713747
Alternative Splicing GalleryENSG00000162889
Gene ExpressionMAPKAPK2 [ NCBI-GEO ]   MAPKAPK2 [ EBI - ARRAY_EXPRESS ]   MAPKAPK2 [ SEEK ]   MAPKAPK2 [ MEM ]
Gene Expression Viewer (FireBrowse)MAPKAPK2 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevestigatorExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)9261
GTEX Portal (Tissue expression)MAPKAPK2
Human Protein AtlasENSG00000162889-MAPKAPK2 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP49137   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP49137  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP49137
Splice isoforms : SwissVarP49137
PhosPhoSitePlusP49137
Domaine pattern : Prosite (Expaxy)PROTEIN_KINASE_ATP (PS00107)    PROTEIN_KINASE_DOM (PS50011)    PROTEIN_KINASE_ST (PS00108)   
Domains : Interpro (EBI)Kinase-like_dom    MAPKAPK_C    Prot_kinase_dom    Protein_kinase_ATP_BS    Ser/Thr_kinase_AS   
Domain families : Pfam (Sanger)Pkinase (PF00069)   
Domain families : Pfam (NCBI)pfam00069   
Domain families : Smart (EMBL)S_TKc (SM00220)  
Conserved Domain (NCBI)MAPKAPK2
DMDM Disease mutations9261
Blocks (Seattle)MAPKAPK2
PDB (SRS)1KWP    1NXK    1NY3    2JBO    2JBP    2OKR    2ONL    2OZA    2P3G    2PZY    3A2C    3FPM    3FYJ    3FYK    3GOK    3KA0    3KC3    3KGA    3M2W    3M42    3R2B    3R2Y    3R30    3WI6    4TYH   
PDB (PDBSum)1KWP    1NXK    1NY3    2JBO    2JBP    2OKR    2ONL    2OZA    2P3G    2PZY    3A2C    3FPM    3FYJ    3FYK    3GOK    3KA0    3KC3    3KGA    3M2W    3M42    3R2B    3R2Y    3R30    3WI6    4TYH   
PDB (IMB)1KWP    1NXK    1NY3    2JBO    2JBP    2OKR    2ONL    2OZA    2P3G    2PZY    3A2C    3FPM    3FYJ    3FYK    3GOK    3KA0    3KC3    3KGA    3M2W    3M42    3R2B    3R2Y    3R30    3WI6    4TYH   
PDB (RSDB)1KWP    1NXK    1NY3    2JBO    2JBP    2OKR    2ONL    2OZA    2P3G    2PZY    3A2C    3FPM    3FYJ    3FYK    3GOK    3KA0    3KC3    3KGA    3M2W    3M42    3R2B    3R2Y    3R30    3WI6    4TYH   
Structural Biology KnowledgeBase1KWP    1NXK    1NY3    2JBO    2JBP    2OKR    2ONL    2OZA    2P3G    2PZY    3A2C    3FPM    3FYJ    3FYK    3GOK    3KA0    3KC3    3KGA    3M2W    3M42    3R2B    3R2Y    3R30    3WI6    4TYH   
SCOP (Structural Classification of Proteins)1KWP    1NXK    1NY3    2JBO    2JBP    2OKR    2ONL    2OZA    2P3G    2PZY    3A2C    3FPM    3FYJ    3FYK    3GOK    3KA0    3KC3    3KGA    3M2W    3M42    3R2B    3R2Y    3R30    3WI6    4TYH   
CATH (Classification of proteins structures)1KWP    1NXK    1NY3    2JBO    2JBP    2OKR    2ONL    2OZA    2P3G    2PZY    3A2C    3FPM    3FYJ    3FYK    3GOK    3KA0    3KC3    3KGA    3M2W    3M42    3R2B    3R2Y    3R30    3WI6    4TYH   
SuperfamilyP49137
Human Protein Atlas [tissue]ENSG00000162889-MAPKAPK2 [tissue]
Peptide AtlasP49137
HPRD11882
IPIIPI00026054   IPI00215763   
Protein Interaction databases
DIP (DOE-UCLA)P49137
IntAct (EBI)P49137
FunCoupENSG00000162889
BioGRIDMAPKAPK2
STRING (EMBL)MAPKAPK2
ZODIACMAPKAPK2
Ontologies - Pathways
QuickGOP49137
Ontology : AmiGOMAPK cascade  activation of MAPK activity  toll-like receptor signaling pathway  protein kinase activity  protein serine/threonine kinase activity  protein serine/threonine kinase activity  protein serine/threonine kinase activity  calmodulin-dependent protein kinase activity  signal transducer activity  protein binding  calmodulin binding  ATP binding  nucleus  nucleoplasm  nucleoplasm  cytoplasm  centrosome  cytosol  protein phosphorylation  leukotriene metabolic process  response to stress  inflammatory response  inflammatory response  cellular response to DNA damage stimulus  Ras protein signal transduction  calcium-dependent protein serine/threonine kinase activity  peptidyl-serine phosphorylation  G2 DNA damage checkpoint  response to lipopolysaccharide  regulation of interleukin-6 production  regulation of tumor necrosis factor production  response to cytokine  cellular response to vascular endothelial growth factor stimulus  p38MAPK cascade  positive regulation of tumor necrosis factor biosynthetic process  regulation of mRNA stability  macropinocytosis  protein autophosphorylation  vascular endothelial growth factor receptor signaling pathway  vascular endothelial growth factor receptor signaling pathway  inner ear development  extracellular exosome  3'-UTR-mediated mRNA stabilization  regulation of cellular response to heat  
Ontology : EGO-EBIMAPK cascade  activation of MAPK activity  toll-like receptor signaling pathway  protein kinase activity  protein serine/threonine kinase activity  protein serine/threonine kinase activity  protein serine/threonine kinase activity  calmodulin-dependent protein kinase activity  signal transducer activity  protein binding  calmodulin binding  ATP binding  nucleus  nucleoplasm  nucleoplasm  cytoplasm  centrosome  cytosol  protein phosphorylation  leukotriene metabolic process  response to stress  inflammatory response  inflammatory response  cellular response to DNA damage stimulus  Ras protein signal transduction  calcium-dependent protein serine/threonine kinase activity  peptidyl-serine phosphorylation  G2 DNA damage checkpoint  response to lipopolysaccharide  regulation of interleukin-6 production  regulation of tumor necrosis factor production  response to cytokine  cellular response to vascular endothelial growth factor stimulus  p38MAPK cascade  positive regulation of tumor necrosis factor biosynthetic process  regulation of mRNA stability  macropinocytosis  protein autophosphorylation  vascular endothelial growth factor receptor signaling pathway  vascular endothelial growth factor receptor signaling pathway  inner ear development  extracellular exosome  3'-UTR-mediated mRNA stabilization  regulation of cellular response to heat  
Pathways : BIOCARTAp38 MAPK Signaling Pathway [Genes]    MAPKinase Signaling Pathway [Genes]    Stress Induction of HSP Regulation [Genes]   
Pathways : KEGGMAPK signaling pathway    VEGF signaling pathway    Neurotrophin signaling pathway    Viral carcinogenesis   
REACTOMEP49137 [protein]
REACTOME PathwaysR-HSA-450513 [pathway]   
NDEx NetworkMAPKAPK2
Atlas of Cancer Signalling NetworkMAPKAPK2
Wikipedia pathwaysMAPKAPK2
Orthology - Evolution
OrthoDB9261
GeneTree (enSembl)ENSG00000162889
Phylogenetic Trees/Animal Genes : TreeFamMAPKAPK2
HOVERGENP49137
HOGENOMP49137
Homologs : HomoloGeneMAPKAPK2
Homology/Alignments : Family Browser (UCSC)MAPKAPK2
Gene fusions - Rearrangements
Fusion : MitelmanMAPKAPK2/SRGAP2 [1q32.1/1q32.1]  
Fusion: TCGA_MDACCMAPKAPK2 1q32.1 SRGAP2 1q32.1 HNSC
Tumor Fusion PortalMAPKAPK2
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerMAPKAPK2 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)MAPKAPK2
dbVarMAPKAPK2
ClinVarMAPKAPK2
1000_GenomesMAPKAPK2 
Exome Variant ServerMAPKAPK2
ExAC (Exome Aggregation Consortium)ENSG00000162889
GNOMAD BrowserENSG00000162889
Genetic variants : HAPMAP9261
Genomic Variants (DGV)MAPKAPK2 [DGVbeta]
DECIPHERMAPKAPK2 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisMAPKAPK2 
Mutations
ICGC Data PortalMAPKAPK2 
TCGA Data PortalMAPKAPK2 
Broad Tumor PortalMAPKAPK2
OASIS PortalMAPKAPK2 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICMAPKAPK2  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDMAPKAPK2
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch MAPKAPK2
DgiDB (Drug Gene Interaction Database)MAPKAPK2
DoCM (Curated mutations)MAPKAPK2 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)MAPKAPK2 (select a term)
intoGenMAPKAPK2
NCG5 (London)MAPKAPK2
Cancer3DMAPKAPK2(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM602006   
Orphanet
DisGeNETMAPKAPK2
MedgenMAPKAPK2
Genetic Testing Registry MAPKAPK2
NextProtP49137 [Medical]
TSGene9261
GENETestsMAPKAPK2
Target ValidationMAPKAPK2
Huge Navigator MAPKAPK2 [HugePedia]
snp3D : Map Gene to Disease9261
BioCentury BCIQMAPKAPK2
ClinGenMAPKAPK2
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD9261
Chemical/Pharm GKB GenePA30631
Clinical trialMAPKAPK2
Miscellaneous
canSAR (ICR)MAPKAPK2 (select the gene name)
Probes
Litterature
PubMed151 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineMAPKAPK2
EVEXMAPKAPK2
GoPubMedMAPKAPK2
iHOPMAPKAPK2
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Nov 21 14:55:14 CET 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.